share_log

TransMedics | 8-K: TransMedics Reports Second Quarter 2024 Financial Results

TransMedics | 8-K: TransMedics Reports Second Quarter 2024 Financial Results

TransMedics | 8-K:TransMedics公佈2024年第二季度財務業績
美股SEC公告 ·  2024/08/01 05:12

Moomoo AI 已提取核心訊息

TransMedics Group, Inc. reported strong financial results for Q2 2024, with total revenue of $114.3 million, a 118% increase YoY. The company generated net income of $12.2 million or $0.35 per diluted share, compared to a net loss in Q2 2023. Growth was driven by increased utilization of the Organ Care System (OCS) and the launch of TransMedics logistics services.Gross margin was 61%, down from 70% in Q2 2023 due to a higher proportion of service revenue. Operating expenses increased to $56.8 million, reflecting investments in R&D and organizational growth. Cash position remained strong at $362.8 million as of June 30, 2024.Based on these results, TransMedics raised its full-year 2024 revenue guidance to $425-$445 million, representing 76-84% growth YoY. The company also highlighted recent achievements, including the expansion of its aircraft fleet and the publication of its 2023 ESG update report.
TransMedics Group, Inc. reported strong financial results for Q2 2024, with total revenue of $114.3 million, a 118% increase YoY. The company generated net income of $12.2 million or $0.35 per diluted share, compared to a net loss in Q2 2023. Growth was driven by increased utilization of the Organ Care System (OCS) and the launch of TransMedics logistics services.Gross margin was 61%, down from 70% in Q2 2023 due to a higher proportion of service revenue. Operating expenses increased to $56.8 million, reflecting investments in R&D and organizational growth. Cash position remained strong at $362.8 million as of June 30, 2024.Based on these results, TransMedics raised its full-year 2024 revenue guidance to $425-$445 million, representing 76-84% growth YoY. The company also highlighted recent achievements, including the expansion of its aircraft fleet and the publication of its 2023 ESG update report.
TransMedics集團公司報告了2024年第二季度強勁的財務業績,總營業收入爲11430萬美元,同比增長118%。公司實現了凈利潤1220萬美元,每股攤薄收益爲0.35美元,與2023年第二季度的淨虧損相比,增長顯著。增長主要得益於器官護理系統(OCS)的使用增加以及TransMedics物流服務的推出。毛利率爲61%,低於2023年第二季度的70%,這主要是由於服務收入所佔比例增加。營業費用增加到5680萬美元,反映出在研發和組織增長方面的投資。截至2024年6月30日,現金狀況仍保持強勁,達到36280萬美元。基於這些結果,TransMedics將其2024年全年營業收入指引上調至425-$44500萬,表示同比增長76-84%。公司還強調了近期的成就,包括擴大航空器艦隊和發佈2023年ESG更新報告。
TransMedics集團公司報告了2024年第二季度強勁的財務業績,總營業收入爲11430萬美元,同比增長118%。公司實現了凈利潤1220萬美元,每股攤薄收益爲0.35美元,與2023年第二季度的淨虧損相比,增長顯著。增長主要得益於器官護理系統(OCS)的使用增加以及TransMedics物流服務的推出。毛利率爲61%,低於2023年第二季度的70%,這主要是由於服務收入所佔比例增加。營業費用增加到5680萬美元,反映出在研發和組織增長方面的投資。截至2024年6月30日,現金狀況仍保持強勁,達到36280萬美元。基於這些結果,TransMedics將其2024年全年營業收入指引上調至425-$44500萬,表示同比增長76-84%。公司還強調了近期的成就,包括擴大航空器艦隊和發佈2023年ESG更新報告。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息